摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Cyclopentanecarboxylic acid 3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-5-isopropyl-6-oxo-6H-pyridazin-1-ylmethyl ester | 1133711-10-0

中文名称
——
中文别名
——
英文名称
Cyclopentanecarboxylic acid 3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-5-isopropyl-6-oxo-6H-pyridazin-1-ylmethyl ester
英文别名
[3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-1,2,4-triazin-2-yl)phenoxy]-6-oxo-5-propan-2-ylpyridazin-1-yl]methyl cyclopentanecarboxylate
Cyclopentanecarboxylic acid 3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-5-isopropyl-6-oxo-6H-pyridazin-1-ylmethyl ester化学式
CAS
1133711-10-0
化学式
C24H22Cl2N6O6
mdl
——
分子量
561.381
InChiKey
DYWNFIMMYBYAGF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.57±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    38
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    154
  • 氢给体数:
    1
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-[3,5-dichloro-4-(1-chloromethyl-5-isopropyl-6-oxo-1,6-dihydro-pyridazin-3-yloxy)-phenyl]-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine-6-carbonitrile环戊酸 在 silver(I) oxide methanol-dichloromethane 作用下, 以 乙腈 为溶剂, 反应 72.0h, 以afforded cyclopentanecarboxylic acid 3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-5-isopropyl-6-oxo-6H-pyridazin-1-ylmethyl ester (75.7 mg, 21%) as an off-white solid的产率得到Cyclopentanecarboxylic acid 3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-5-isopropyl-6-oxo-6H-pyridazin-1-ylmethyl ester
    参考文献:
    名称:
    Prodrugs of thyroid hormone analogs
    摘要:
    本文提供了式(I)的化合物及其药学上可接受的盐,其中取代基如规范中所述。这些化合物及含有它们的药物组合物,用于治疗肥胖症、高脂血症、高胆固醇血症、糖尿病和其他相关疾病,以及可能对NASH、动脉硬化、心血管疾病、甲状腺功能减退症、甲状腺癌和其他相关疾病有用。
    公开号:
    US08076334B2
点击查看最新优质反应信息

文献信息

  • PRODRUGS OF THYROID HORMONE ANALOGS
    申请人:HAYNES NANCY-ELLEN
    公开号:US20090082310A1
    公开(公告)日:2009-03-26
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.
    本文提供了以下式(I)的化合物: 以及其药学上可接受的盐,其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗肥胖、高脂血症、高胆固醇血症和糖尿病等疾病非常有用,也可能对其他疾病如NASH、动脉粥样硬化、心血管疾病、甲状腺功能减退症、甲状腺癌及其他相关疾病和疾病有用。
  • PRODRUGS TO THYROID HORMONE ANALOGS
    申请人:F. Hoffmann-La Roche AG
    公开号:EP2203443B1
    公开(公告)日:2014-03-05
  • US8076334B2
    申请人:——
    公开号:US8076334B2
    公开(公告)日:2011-12-13
  • [EN] PRODRUGS TO THYROID HORMONE ANALOGS<br/>[FR] PROMÉDICAMENTS POUR ANALOGUES DE L'HORMONE THYROÏDIENNE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2009037172A1
    公开(公告)日:2009-03-26
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.
  • Prodrugs of thyroid hormone analogs
    申请人:Hoffmann-La Roche Inc.
    公开号:US08076334B2
    公开(公告)日:2011-12-13
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.
    本文提供了式(I)的化合物及其药学上可接受的盐,其中取代基如规范中所述。这些化合物及含有它们的药物组合物,用于治疗肥胖症、高脂血症、高胆固醇血症、糖尿病和其他相关疾病,以及可能对NASH、动脉硬化、心血管疾病、甲状腺功能减退症、甲状腺癌和其他相关疾病有用。
查看更多